Evidence map›Paper›PMID 30840433›Full record

ArticleACS nano2019

Biomimetic Glyconanoparticle Vaccine for Cancer Immunotherapy.

Eliran Moshe Reuven, Shani Leviatan Ben-Arye, Hai Yu, Roberto Duchi, Andrea Perota, Sophie Conchon, Shirley Bachar Abramovitch, Jean-Paul Soulillou, Cesare Galli, Xi Chen and 1 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS nano, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 54 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Biomimetic Glyconanoparticle Nanoghost Vaccine Based on Red Blood Cells.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  5. Current Landscape of Therapeutic Cancer Vaccines.Methods in molecular biology (Clifton, N.J.) · 2025
    Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 4 countries.

Eliran Moshe ReuvenDepartment of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences , Tel Aviv University , Tel Aviv 69978 , Israel.
Shani Leviatan Ben-AryeDepartment of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences , Tel Aviv University , Tel Aviv 69978 , Israel.
Hai YuDepartment of Chemistry , University of California , Davis , California 95616 , United States.ORCID 0000-0002-4378-0532
Roberto DuchiAvantea , Laboratory of Reproductive Technologies , Via Porcellasco 7/F , 26100 Cremona , Italy.
Andrea PerotaAvantea , Laboratory of Reproductive Technologies , Via Porcellasco 7/F , 26100 Cremona , Italy.
Sophie ConchonInstitut de Transplantation-Urologie-Néphrologie , INSERM Unité Mixte de Recherche 1064, Centre Hospitalo Universitaire de Nantes , Nantes 44000 , France.
Shirley Bachar AbramovitchDepartment of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences , Tel Aviv University , Tel Aviv 69978 , Israel.
Jean-Paul SoulillouInstitut de Transplantation-Urologie-Néphrologie , INSERM Unité Mixte de Recherche 1064, Centre Hospitalo Universitaire de Nantes , Nantes 44000 , France.
Cesare GalliAvantea , Laboratory of Reproductive Technologies , Via Porcellasco 7/F , 26100 Cremona , Italy.
Xi ChenDepartment of Chemistry , University of California , Davis , California 95616 , United States.ORCID 0000-0002-3160-614X
Vered Padler-KaravaniDepartment of Cell Research and Immunology, The George S. Wise Faculty of Life Sciences , Tel Aviv University , Tel Aviv 69978 , Israel.ORCID 0000-0002-4761-3571
Tel Aviv University · ILAvantea · ITInserm · FRUniversity of California, Davis · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Gina M Dayton · 2002 to 2026
$84.9M
European Research Council 716220NCI NIH HHS P30 CA093373
6 · The paper itself

Abstract

Cancer immunotherapy aims to harness the immune system to combat malignant processes. Transformed cells harbor diverse modifications that lead to formation of neoantigens, including aberrantly expressed cell surface carbohydrates. Targeting tumor-associated carbohydrate antigens (TACA) hold great potential for cancer immunotherapy. N-glycolylneuraminic acid (Neu5Gc) is a dietary non-human immunogenic carbohydrate that accumulates on human cancer cells, thereby generating neoantigens. In mice, passive immunotherapy with anti-Neu5Gc antibodies inhibits growth of Neu5Gc-positive tumors. Here, we designed an active cancer vaccine immunotherapy strategy to target Neu5Gc-positive tumors. We generated biomimetic glyconanoparticles using engineered αGal knockout porcine red blood cells to form nanoghosts (NGs) that either express (NG

Indexed as

ImmunotherapyAdenocarcinomaAnimalsBiomimetic MaterialsCancer VaccinesColonic NeoplasmsMiceMice, KnockoutN-Acetylneuraminic AcidNanoparticlesNeuraminic AcidsParticle SizeSwineCancer VaccinesN-Acetylneuraminic AcidNeuraminic AcidsN-glycolylneuraminic acidbiomimeticcancer immunotherapyglycan microarrayglyconanoparticleneoantigenN-glycolylneuraminic acidsialic acid

Identifiers

PMID30840433
PMCPMC6756924
OpenAlexW2919992199

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.